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DEVELOPMENT OF REPLICATION-COMPETENT VSV-BASED VACCINES 
FOR PROTECTION AGAINST HANTAVIRUS INFECTION 
 
Co-Chairperson:  Dr. Keith Parker 
 
Co-Chairperson:  Heinz Feldmann 
 
Abstract: 
This study looks at the effects of the position and numbers of foreign 
immunogens in the vesicular stomatitis virus (VSV) genome on vector 
attenuation and vaccine efficacy. To generate the recombinant vaccine vectors, a 
VSV Indiana strain was modified by removing the native VSV glycoprotein and 
replacing it with one or two foreign glycoproteins; one derived from the filovirus 
Zaire ebolavirus (ZEBOVgp) and the other from the hantavirus Andes virus 
(ANDVgpc). Two monovalent (rVSVΔG-ANDVgpc and rVSVΔG-ZEBOVgp) and 
two bivalent (rVSVΔG-ANDVgpc-ZEBOVgp and rVSVΔG-ZEBOVgp-ANDVgpc 
recombinant vectors were compared. All vectors were attenuated in cell culture 
and in immunocompetent hamsters when compared to rVSV wildtype (rVSVwt). 
rVSVΔG-ZEBOVgp and other unrelated monovalent rVSV vectors did show 
pathogenicity in an immunocompromised mouse model making this model 
unsuitable for vaccine efficacy testing. rVSV vaccine vector efficacy testing was 
explored in the established lethal ANDV hamster model. In addition, two routes of 
immunization, intraperitoneal and intranasal, were compared. The two bivalent 
vectors both mediated full protection when administered even 3 days prior to 
ANDV challenge independent of the route of immunization. The monovalent 
rVSVΔG-ANDVgpc was similarly protective but intranasal immunization showed 
reduced efficacy when administered close to challenge. The bivalent rVSVΔG-
ZEBOVgp-ANDVgpc was most potent in post-exposure treatment, followed by 
the monovalent rVSVΔG-ZEBOVgp. The monovalent rVSVΔG-ANDVgpc was 
least potent in post-exposure treatment. Intraperitoneal immunization was 
superior over the intranasal route in post-exposure treatment. Our data indicates 
the benefit of bivalent rVSV vaccine vectors based on the rVSVΔG-ZEBOVgp 
backbone with the second immunogen expressed in the downstream position in 
peri-exposure application. 
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	 PRELUDE 
In this dissertation, ongoing work toward developing replication-
competent viral-based vaccines against a selected hantavirus is described.  
In Chapter 1, an introduction to hantaviruses, their biogeography and life 
cycle, and the zoonotic human diseases that they cause is provided. This is 
followed by an introduction to Vesicular Stomatitis Virus (VSV) which is 
commonly used as an experimental vaccine platform. The chapter concludes 
with an overview of the core problem or “scientific question” addressed as part of 
the work that is presented in subsequent chapters of the thesis. 
In Chapter 2, an expanded discussion on the advantages and 
disadvantages, benefits and limitations of employing a rVSV platform for vaccine 
development against deadly negative single-strand RNA (–ssRNA) viruses is 
provided.  This chapter is based on work completed in 2009-2015 and recently 
published (October, 2015). Specifically, the efficacy of rVSV-based vaccines in 
distinct animal models is considered.  This background information and work 
presented in Chapter 2 forms the basis for the model used for the core research 
effort presented in Chapter 3.  
In Chapter 3, a series of experiments in the Syrian Golden hamster 
(Mesocricetus auratus) model system demonstrates pre- and post-exposure 
protection using rVSV-based vaccines against the human pathogenic hantavirus, 
Andes virus. Data demonstrate significant post-exposure protection against 
hantavirus with these rVSV-based vaccines compared to previously reported 
vaccine constructs. 
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	 In the final chapter (Chapter 4), future directions for design and 
development of replication-competent rVSV-based vaccines are discussed. The 
approaches and lines of experimentation described extend beyond the scope of 
this dissertation project and forward this work to a point where these rVSV-based 
vaccines may be used in other animal model systems thereby testing the utility of 
these constructs. Implementation of replication-competent vaccines (rVSV-based 
or otherwise) as standard medical practice remains controversial.  However, the 
emergence of, and inability to predict and control devastating outbreaks of highly 
pathogenic viruses may result in the future testing and use of this class of 
vaccines in humans.  
Cumulatively, the body of work presented in this thesis contributes to a 
larger body of literature on novel approaches to vaccine development and the 
focus area of developing replication-competent vaccines for emergency use.  It 
further demonstrates how vaccine platforms such as rVSV-based vectors can be 
tailored to elicit specific responses while decreasing side effects often seen with 
traditional vaccines.  
  
Marceau,	Joshua	O.,	Ph.D.,	Fall	2016	 	 Department	of	Biomedical	Sciences	
3	
	 CHAPTER 1 INTRODUCTION 
Hantaviruses and a Rhabdovirus Reverse Genetic System 
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	 Hantaviruses: Introduction 
 
Hantaviruses are a group of zoonotic pathogens that are part of the virus 
family Bunyaviridae.  Hantaviruses present as a single-stranded segmented RNA 
genome of approximately 12.1 kb divided into three segments: a large segment 
(L), a medium segment (M), and a small segment (S) of RNA lengths 6.5 kb, 3.6-
3.7 kb, and, 1.6-2 kb, respectively (Schonrich et al. 2008). The hantavirus virion 
presents as an enveloped pleomorphic pseudo-spherical particle with a diameter 
ranging from 80-120 nm (Schonrich et al. 2008).  Interestingly, each of the three 
RNA segments comprising the virion are packaged in a separate nucleocapsid. 
The three nucleocapsids are bound within the virus particle and surrounded by a 
common cell-derived lipid bilayer featuring the viral glycoprotein spike complex 
(Plyusnin et al. 1996; Vaheri et al. 2013).  
The hantaviruses differ from the rest of the Bunyaviridae family in that they 
are the only group that are transmitted by a rodent vector. It has been proposed 
that hantavirus transmission can occur through the inhalation of dried rodent 
excreta (Colleen et al. 2010). In contrast, the other genera of bunyaviruses are all 
arthropod-borne (Plyusnin et al. 1996; Liu et al. 2012). Hantavirus genotypes are 
commonly grouped together based on their biogeography.  Those from Europe 
and Asia are known as the “Old World” hantaviruses whereas those found in 
North America and South America are known as ”New World” hantaviruses 
(Figure 1-1).  All hantaviruses are non-pathogenic in their natural hosts and 
indeed many do not cause disease in humans.  However, several hantaviruses of 
both “Old World” and “New World” lineages can cause severe disease in 
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	 humans. (Hantaviruses that cause disease in humans are classified as 
Biosafety Level 3 pathogens because of the threat of severe disease without 
the availability of therapeutic treatments or preventative vaccines). 
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Figure	1-1:	Hantavirus	Global	Distribution	Map. 	
The map above depicts the global distribution of hantaviruses which is closely 
mirrored with the ranges of their natural hosts. Used with permission of Dr. David 
Safronetz 2016. 
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	 Hantaviruses: History 
 
Based on historical descriptions of symptoms for a variety of human 
ailments, it has been suggested that hantaviruses have been responsible for 
human disease for at least a century (Khaiboullina et al. 2005). However, the first 
well-documented emergence of hantavirus-induced disease in humans occurred 
during the Korean War where several thousand troops from the United Nations 
contracted an acute febrile illness, which was initially designated “Korean 
hemorrhagic fever” (Jonsson et. al 2010). This disease, now referred to as 
hemorrhagic fever with renal syndrome (HFRS), is characterized by intense 
headaches, fever, chills, and abdominal pain followed by later symptoms which 
can include low blood pressure, kidney failure, vascular leakage and other 
hemorrhagic manifestations (Linderholm et al. 2001). The causative agent was 
later identified (ca. 1970s) as a virus from field mice (Apodemus agrarius) (Lee et 
al.1978). The virus was named Hantaan Virus from the region where the host 
rodent was captured - near the Hantaan River between North and South Korea, 
close to the 38th parallel (Lee et al. 1982; Lindkvist et al. 2008).  
Today, hantaviruses continue to be among some of the most concerning 
etiological agents of emergent zoonotic infectious diseases and are considered a 
significant threat worldwide. The viruses are maintained in reservoirs of natural 
hosts. Geographic distribution of these natural hosts and epidemiology 
associated with these viruses are congruent.   
In the Old World, the majority of hantavirus cases have been reported in 
Europe (e.g., Russia) and Eastern Asia.  For example, hantavirus is widespread 
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	 in China. Some reports estimate that hantavirus-induced disease in China 
accounts for ~90% of the world’s recorded cases per year (Liu et al. 2012).  
The Hubei province of central China has often recorded the highest annual 
occurrence of HFRS in the world.  Over the last 20 years, rapid urbanization in 
China has undoubtedly contributed to the increasing rate of HFRS.  Rapid 
socioeconomic growth, modern transportation, and extensive migration from rural 
to urban areas has contributed to an expanded geographic range for natural 
hantavirus hosts. The concomitant increase in human population density in 
Chinese cities has resulted in an increase in the frequency of cases in Northern 
China (e.g., Beijing and Mongolia), a region where cases have historically been 
rare to nonexistent (Liu et al. 2012). 
In the New World, at least two highly virulent strains of hantavirus have 
been well-characterized. Although hantavirus diseases occur less frequently in 
the Americas, the lethality rates can reach as high as 40% with some of the more 
pathogenic strains (Safronetz et al. 2009). 
Since the isolation of the first New World hantavirus in 1993 (Nichol et al. 
1993), cases of hantavirus-induced human disease have been reported in the 
western region of the United States and several countries in Central and South 
America. However, disease induced by New World hantaviruses differs 
significantly from that caused by hantaviruses in Europe and Asia.  Specifically, 
New World hantavirus results in vascular leakage in the lungs, pulmonary 
edema, and cardiovascular collapse.  The disease is called Hantavirus 
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	 Cardiopulmonary Syndrome (HCPS).  Two species of the virus are responsible 
for HCPS: Sin Nombre Virus (SNV) and Andes Virus (ANDV). 
SNV was isolated in 1993 in the southwestern United States (i.e., New 
Mexico).  SNV is highly virulent, resulting in up to 35% lethality (Schonrich et al. 
2008). ANDV was subsequently isolated in 1997 after an outbreak in Chile and 
was later responsible for additional HCPS outbreaks in both Chile and Argentina 
(Lopez et al. 1997).  Of the 22 described hantaviruses, ANDV is considered one 
of the “most deadly” hantaviruses (Schonrich et al. 2015). Outbreaks of ANDV 
have been reported to cause case fatality rates exceeding 40%. It is also the only 
hantavirus capable of transmission directly from human–to–human (Martinez-
Valdebenito et al. 2014). 
Hantavirus-induced diseases including HFRS and HCPS continue to 
emerge (and re-emerge) worldwide with annual documented case totals in 
Europe and Asia reaching up to 200,000 and case fatality rates as high as 10% 
(Safronetz et al. 2011). Despite causing unique symptomology, both hantavirus-
induced diseases cause vascular leakage and thrombocytopenia. North 
American and South American strains of SNV and ANDV continue to be the most 
devastating in terms of mortality (Clement et al 2014).  
 
Response to Hantaviruses 
 
The clinical manifestation of hantavirus infection in humans is acute 
affecting renal, cardiac, pulmonary, central nervous system, and endocrine 
function.  Two separate hantavirus-induced diseases in humans have been 
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	 defined and studied – HFRS caused by Old World hantavirus and HCPS 
caused by New World hantavirus.  HFRS is characterized by a high fever which 
can be accompanied by headache, abdominal pains, backache and kidney 
dysfunctions. HFRS disease is highly variable and is thought to depend heavily 
on the hantavirus genotype and host genetic factors (Vaheri et al. 2013). HCPS 
is also a severe disease which is often associated with respiratory failure from 
pulmonary edema (Duchin et al. 1994). Despite causing separate diseases, Old 
World and New World hantaviruses share common features at the cellular level 
leading to detrimental impact on the host.  These effects include an acute phase 
characterized by the aforementioned symptoms but may also lead to long-term or 
“chronic” debilitation.  Specifically, hantaviruses infect and replicate primarily in 
endothelial cells increasing capillary permeability. Altering capillary permeability 
results in extravasation of fluid into alveolar spaces causing hypotension, 
pulmonary edema, and thrombocytopenia (Vaheri et al. 2013). Interestingly, the 
viral infection does not appear to cause notable cytopathic effects or cellular 
necrosis. Instead, it is proposed that infection of endothelial layers modulates an 
immuno-pathological response that is activated by infected endothelial cells and 
migrating blood mononuclear cells (Khaiboullina et al. 2005).  Frankly, the exact 
mechanism by which immunopathology ensues after hantavirus infection is 
poorly understood and continues to be a core focus of current research 
(Schonrich et al. 2008). 
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	 Natural Reservoirs of Hantaviruses 
 
Hantaviruses have a unique coevolutionary history with their specific 
host rodent species. This relationship between the virus and the natural host 
species has resulted in persistence of the virus which causes no signs of disease 
in the rodent population. It appears that the virus/host systems are highly co-
evolved and viral persistence, in the absence of disease, is mediated by both the 
virus and the host to ensure the survival by both. (Easterbrook et al. 2008). 
Laboratory-infected animals are not able to completely clear the virus, and it is 
speculated that low levels of viral replication persist over the lifetime of the 
animal accompanied with the persistent shedding of that virus in the host urine, 
feces and saliva.  
It appears that the hantavirus infection is spread through the rodent 
population when exposed to contaminated dust from the excretia of other 
infected rodents, as well as biting and scratching behavior between individuals. 
The grooming habits of animals and their cagemates has also been observed 
and thought to contribute as well (Hw et al. 1981). Maternal transmission to 
offspring is not thought to be a major route of transmission due to passive 
transfer of protective maternal antibodies though milk (Botten et al. 2002;  
Dohmae et al. 1995).  
Of the most common strains of hantavirus that occur in the old world the 
natural reservoirs tend to be associated with 2 families of rodents Murinae and 
Arvicolinae. The new world hantavirus typically has hosts in the rodent subfamily 
Sigmodontinae (Schonrich et al. 2008; Khaiboullina et al. 2005). In that only a 
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	 small percentage of rodents and insectovore species have been tested for 
hantavirus infection, it is expected that many more species of hantavirus will be 
discovered in the future (Plyusnin et al. 1996). 
 
Biology and Life Cycle of Hantaviruses 
 
The viral RNA segments are designated as the S, L, and M segments and 
encode the nucleocapsid protein (NP), the viral RNA polymerase (RdRp), and 
the glycoprotein precursor (GPC), respectively (Löber et al. 200).  
Hantaviruses are thought to enter their host cells via a clathrin dependent 
endocytosis mechanism (Jin et al. 2002) through the use of integrin receptors 
(Wickham et al. 1994; Roivainen et al. 1994; Jackson et al. 1997; Guerrero et al. 
2000). The human integrin alpha(v)beta(3) is one receptor that is expressed on 
human endothelial cells and allows entry of HFRS and HCPs causing hantavirus 
species (Gavrilovskaya et al. 2008). Interestingly, several species of non-
pathogenic hantaviruses have been shown to use the alpha(v)beta(1) integrin 
(Gavrilovskaya et al. 2002).  
After the virus particle is internalized the RNA segments are released into 
the cytoplasm accompanied by an RNA dependent RNA polymerase (RdRp) 
which initiates primary transcription of viral proteins (Jin et al. 2002). Once the 
production of viral components have accumulated to the proper levels, the 
remaining morphogenesis, which is not completely understood, is completed as 
the virus buds in the Golgi (Figure 1-2) (Plyusnin et al. 1996).    
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	 The majority of hantavirus species that cause HFRS and HPS do not 
cause cytopathic effects in most cell types.  Therefore, virus-induced disease is 
likely caused by indirect mechanisms including the host immune response and 
disregulation of the chemokine and cytokine responses.  Because the main 
target cells are endothelial cells, it is thought that hantavirus disease and 
pathogenesis is linked to the cellular response activated in endothelial cells.  
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Figure	1-2:	Hantavirus	life	cycle	schematic. 	
Represents the major steps in the lifecycle of a hantavirus in the host cell. 
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	 The viral glycoprotein is synthesized as a glycoprotein precursor 
molecule by ribosomes bound to the endoplasmic reticulum (Pensiero et al. 
1992; Schmaljohn et al. 1987; Khaiboullina et al. 2005). The precursor 
molecule is then translocated to the ER via a signal peptide where it is cleaved 
by the signal peptidase at a cut site with conserved amino acid sequence of 
“WAASA” into the two glycoprotein subunits G1 and G2 (Löber et al. 2001). 
Formation of the G1/G2 complex allows translocation to the Golgi where the final 
maturation steps take place and become ready for viral assembly. The 
cytoplasmic tails of the G1/G2 complex interact with the nuclear protein/viral RNA 
complex and initiate viral budding from the Golgi. The newly-formed viral 
particles are then transported to the plasma membrane where viral egress takes 
place (Vaheri et al. 2013). 
Some	of	the	major	hurdles	in	studying	hantavirus	infection	and	its	influence	
on	the	host	immune	response	is	the	limited	availability	of	animal	models.	The	only	
adult	small	animal	disease	model	currently	available	is	the	ANDV	infection	of	the	
Syrian	golden	hamster	(Safronetz	et	al.	2012).	While	the	use	of	a	STAT1	knock	out	
mouse	model	was	explored	in	chapter	2	it	was	not	intended	for	use	as	a	lethal	ANDV	
challenge	model.	An	immunocompromised	mouse	model	would	be	valuable	as	a	
model	for	rVSV	vector	efficacy	in	stimulating	the	immune	system	when	paired	with	
commonly	available	reagents	for	exploring	the	in	vivo	immune	response	in	murine	
models.	Thus,	chapter	2	explores	the	use	of	the	STAT1	knock	out	mouse	model	
and	forms	the	basis	for	the	decision	to	use	the	hamster	model	in	the	research	
presented	in	Chapter	3.	In	addition,	two	nonhuman	primate	disease	models	have	
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	 been	described,	one	for	Sin	nombre	virus	(Safronetz	et	al.	2014)	and	the	other	one	
for	Puumala	virus	(Groen	et	al.	1995),	but	neither	are	well	established	at	this	time.		
This	leaves	the	ANDV	hamster	disease	model	as	the	currently	best	choice	for	
hantavirus	vaccine	efficacy	testing.		
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	 Vesicular Stomatitis Virus (VSV) Background 
 
VSV as a Vaccine Platform 
 As our knowledge of the immune response and vaccines increase, the 
scientific and medical fields will have a greater ability to design tools against 
human disease. Vaccines that are specifically designed to mediate an effective 
immune response and elicit a custom tailored response to a specific disease can 
be more efficient and have reduced side effects. Viruses that are designed to 
stimulate specific immune responses are getting more attractive and rVSV has 
been proven to be a very promising platform to develop viral therapeutics.  
 Because VSV is an RNA virus it is thought that problems associated with 
DNA virus based platforms could be circumvented with the RNA based rVSV 
platform by avoiding viral replication in a cell's nucleus. DNA virus-based 
therapeutics have come under scrutiny because of the possibility of the virus to 
cause mutations to the host cell’s DNA in addition to the disruption of host cell 
transcription processes.  
 Because of the wide distribution of phosphatidylserine (the host 
membrane component which VSV glycoprotein (G) binds to in order to facilitate 
entry) in host cells across the domains of life the VSV has an exceptionally broad 
tissue tropism. Replacement of the native VSV-G with other viral glycoproteins 
allows the engineering of recombinant vectors (rVSV) that have more specific 
host tissue/cellular targeting and thus likely less side effects.  
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	  Since the reverse genetics system allows precise tailoring of the virus, it 
can be attenuated by careful manipulation of the genome and the deletion of 
viral pathogenicity factors to reduce side effects while still being replication 
competent. The rVSV vaccine vectors have many other advantages, such as the 
ability to be administered as a single dose and given through other routes such 
as mucosal membranes that do not involve injection but are still able to elicit a 
robust protective immune response (Schlereth et al. 2000; Roberts et al. 1998).  
 The ability to manipulate and grow the virus in the lab is straightforward 
and the virus is easily grown rapidly and to high titers in tissue culture. It grows 
so well that it has been suggested in the rVSV-HIV literature that one liter culture 
of supernatant volume could generate enough vaccine material to vaccinate over 
1 billion people (Rose et al. 2001). Because of these advantages, this study 
focuses on using a rVSV based vector as a vaccine against lethal Andes virus 
Infection. 
VSV Introduction 
 
VSV is a non-segmented negative stranded RNA virus in the family of 
Rhabdoviridae. Approximately 170 members of the Rhabdoviridae have been 
discovered and these members have an extremely wide host range which allow 
infection across two kingdoms of life (Ghanem et al. 2012).  
VSV has a small and simple genome structure which is approximately 11 
kb pairs and is composed of five genes. The genes are arranged in the 3' to 5' 
direction and are arranged in the conserved order N-P-M-G-L. The first gene (N) 
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	 encodes the nucleoprotein which is responsible for forming the nucleocapsid 
around the viral RNA. The P gene encodes the phosphoprotein, which, in 
combination with N, is used for RNA synthesis. The matrix protein (M gene) 
provides the structural system between the nucleocapsid and the viral envelope. 
The G gene encodes the glycoprotein which allows attachment to target cells and 
initiates fusion of the virus particle the host cell membrane. The L gene encodes 
for the viral RNA polymerase which acts as both a viral transcriptase to produce 
viral mRNAs and a replicase which is responsible for producing successive 
copies of the genome.  The three prime end of the N gene contains a 
transcriptional start sequence which initiates transcription until the polymerase 
encounters a series of U residues at the end of the gene. These residues cause 
the polymerase to stutter back-and-forth producing a poly-A tail before the mRNA 
is discharged. The nearby downstream restart signal causes the polymerase to 
re-engage and continue transcription of the next downstream gene. Production of 
a decreasing gradient of mRNAs is produced from the viral genome, where those 
near the 3' end of the genome are produced in much higher quantities. Because 
the polymerase always starts at the 3’ end of the genome and has a chance to 
dissociate at the end of each gene after transcription, and genes that are closer 
to the 5' end of the genome are produced much less abundantly (Figure 1-3).  
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Figure	1-3:	VSV	Transcription. 	
Represents the sequential transcription of viral genes in the VSV genome. 
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	 The order of these genes is highly conserved in this group of viruses and 
is a simple and efficient way to regulate viral gene expression levels. After viral 
N and P proteins have accumulated to high enough levels in the host cell, the 
polymerase is able to synthesize full-length, positive strand, anti-genome RNAs. 
The anti-genome, in turn, serves as a template for synthesis of full-length 
genomes which are incorporated into new virus particles and then bud out of the 
host cell to complete the viral replication cycle. 
 
VSV Infection & Disease in Animals and Humans  
 
Rhabdoviridae hosts include insects, fish, plants, and vertebrates. VSV 
can cause vesicular lesions in domestic animals (cattle, sheep, horses, pigs) 
which self-resolve, and, after healing, leave the animals with no long term ill 
effects. The early clinical symptoms of VSV infection closely mimic the symptoms 
of hoof-and-mouth disease and the mis-diagnosis has the potential to cause 
economic loss.  
Information supporting VSV’s role in human disease is rare. Although VSV  
has been shown to be able to infect humans, it is generally believed to be largely 
asymptomatic  with the viral infection self-resolving (Lichty et al. 2004). VSV is 
endemic in regions ranging from the southern portion of Mexico to the northern 
part of South America, and also occurs as a livestock animal pathogen in several 
states in the US (Flanagan et al. 2001). Although human seroprevalence against 
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	 VSV is reported in these endemic regions, the clinical disease (described as a 
flu-like illness) rates attributed to VSV are low (Roberts et al. 1999).  
 
rVSV Reverse Genetics System 
 
Members of the Rhabdoviridae family have proven to be important 
biomedical tools. Particularly, in the case of VSV, they can easily be genetically 
engineered to become useful research tools such as vectors, vaccines, viral 
tracers in neurotropism studies, and basic viral lifecycle studies. One of the 
primary features that makes VSV so useful is its ability to be manipulated using a 
reverse genetics system. 
Although there are several systems established for rescuing members of 
the Rhabdoviridae family, I used a rescue plasmid encoded T7 RNA polymerase 
system which uses 6 “helper” plasmid containing the genes for N, P, M, G, L and 
the T7 polymerase. 
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Figure	1-4:	VSV	Reverse	Genetics	System. 	
The bivalent vaccine vector rVSVΔG-ZEBOVgp-ANDVgpc was rescued using the 
VSV reverse genetics system by amplifying and cloning the ZEBOVgp and 
ANDVgpc open reading frames into the pATX plasmid downstream of the M 
gene. 
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	 Detailed description of the rVSV rescue system have been described at 
length in previous literature (Figure 1-4) (Garbutt et al. 2004; Tsuda et al. 2011; 
Brown et al. 2011).  Briefly, a mixed culture of Vero cells and 293T cells were 
grown to a confluence of 90%. The cell co-culture was then transfected with the 
rVSV rescue plasmid in addition to the 6 helper plasmids listed above. The 
transfected co-cultures were then maintained for 12-14 days after transfection 
until cytopathic effects (CPE) were observed indicating successful viral rescue 
and replication. 
In this study we explored the ability of using a combination of 
glycoproteins from the vastly different virus strains, Andes virus and Ebola virus, 
to design a more potent and effective vaccine platform that may have broad 
applications for future vaccine development. 
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	 Objectives and Hypothesis 
 
A previous vaccine efficacy study (Brown et al. 2011) focusing on the 
protection of an rVSV vector expressing the ANDV glycoprotein precursor 
(rVSV∆G-ANDVgpc) against lethal ANDV infection used an unrelated rVSV 
vector expressing the ZEBOV glycoprotein (rVSV∆G-ZEBOVgp)  as a negative 
control which was expected to not provide any protection in the lethal ANDV 
infection study. Interestingly, rVSV∆G-ZEBOVgp provided varying degrees of 
protection in hamsters against ANDV infection when administered between 7 
days prior and 3 days after ANDV challenge. This data indicates that rVSV vector 
vaccination can result in unspecific protective efficacy against heterologous 
challenge.  
We hypothesize that the ZEBOVgp will target important immune cells like 
monocytes, macrophages and dendritic cells, which can lead to a rapid and 
enhanced immune response that is broadly protective against heterogeneous 
viral challenge. This response will be a valuable trait for vectors used in peri-
exposure prophylaxis where a rapid, but short lived protective response may 
suppress viral replication and give the adaptive immune response (if an 
appropriate immunogen is provided) a better chance to kick in and offer a longer 
term immunity. 
 In this study, bivalent vaccine vectors (rVSV∆G-ZEBOVgp-ANDVgpc; 
rVSV∆G-ANDVgpc-ZEBOVgp) including the ZEBOVgp will be utilized based on 
the idea that ZEBOVgp may target the vaccine vectors to important immune 
cells, such as monocytes, macrophages and dendritic cells, strongly enhancing 
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	 innate and adaptive immune responses and, thus improve protective efficacy 
against a lethal heterologous ANDV challenge. The study further looks at the 
effects of the insertion and position of the foreign viral glycoproteins (here 
ZEBOV and ANDV) into the genome of rVSV and how it influences the rVSV 
when used as a vaccine utilizing the ANDV hamster challenge model.  
To generate the vaccine vector an Indiana strain of VSV is modified by 
removing the native glycoprotein and replacing it with two other viral proteins, 
ZEBOV gp and ANDV gpc. Two monovalent (rVSVΔG-ANDVgpc and rVSVΔG-
ZEBOVgp) and two bivalent [rVSVΔG-ANDVgpc-ZEBOVgp (Tsuda et al. 2011) 
and rVSVΔG-ZEBOVgp-ANDVgpc] vectors are compared in this study and the 
results are described in chapter 3.  
While the hamster model is sufficient for testing the protective effects of 
vaccines and survival, the shortcomings become very evident when wanting to 
explore the specific mechanisms involved in the resulting changes in survival. 
There is a lack of commercial reagents specific to the hamster which makes it 
very difficult to study the immune response mechanism involved in protection.  It 
would therefore be desirable to have a mouse model available because of the 
available reagents to study response mechanisms in mice. Since it has been 
shown before that immunosuppression of hamsters can result in a lethal model 
for SNV (Brocato et al. 2014) it would be ideal to demonstrate a lethal model of 
ANDV in immunocompromised mice to facilitate the study of the mechanism of 
immune response in mice since there are many more commercial reagents 
available to study immune mechanisms in the murine models. Unfortunately, 
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	 such a murine model does not yet exist. However, as a first step towards 
developing such a model we investigated the possibility of testing selected 
rVSV-based vaccine candidates in such immunocompromised mouse models 
and the results of this work are discussed in chapter 2.  
Because hantaviruses are continually emerging as zoonotic pathogens the 
threat of significant disease in humans have increased the interest in studying 
hantavirus not only to research viral pathogenesis but also to evaluate possible 
medical interventions such as vaccines or other therapeutics. In particular, a fast 
acting vaccine would be particularly important for the Andes virus as it has been 
shown to successfully be transmitted from human-to-human.  
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	 Abstract 
 
STAT1-defiecient mice lack a response to interferon α, β and γ and 
therefore allowing for replication of non-adapted wild-type (wt) Ebola- and 
Marburgviruses. We sought to establish a mouse model for efficacy testing of 
live-attenuated recombinant vesicular stomatitis virus (rVSV)-based filovirus 
vaccine vectors using wt Ebola- and Marburgvirus challenge strains. While 
infection of immunocompetent mice with different rVSV-based filovirus vectors 
did not cause disease, infection of STAT1-deficient mice with the same vectors 
resulted in systemic infection and lethal outcome for the majority of tested rVSVs. 
Despite differences in viral loads, organ tropism was remarkably similar between 
rVSV filovirus vaccine vectors and VSVwt with the exception of the brain. In 
conclusion, STAT1-deficient mice are not an appropriate immunocompromised 
mouse model for efficacy testing of live-attenuated, replication-competent rVSV 
vaccine vectors.   
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	 Introduction 
 
Members of the family Filoviridae, Ebola- and Marburgviruses, are pathogens 
causing viral hemorrhagic fever in nonhuman primates and humans (Feldmann 
et al. 2013). While outbreaks of filovirus hemorrhagic fever have occurred mainly 
in their endemic area in Central Africa, currently, the biggest documented Ebola 
virus (EBOV) outbreak is still ongoing in West African countries such as Guinea, 
Liberia and Sierra Leone. Not only has the virus spread from there into 
neighboring Mali, it was also introduced to Senegal, Nigeria, Spain, the United 
Kingdom and the United States where further spread of the virus was 
successfully stopped (WHO 2015). Despite tremendous effort being made to 
accelerate Phase 1 Clinical trials for experimental vaccines and therapeutics 
(www.ClinicalTrials.gov), there is still no approved countermeasure available. 
One of the experimental vaccine platforms currently in Phase 1 Clinical trials is 
based on recombinant vesicular stomatitis virus (rVSV). The rVSV vaccines for 
EBOV, strain Mayinga (EBOV-May) and Marburg virus (MARV), strain Musoke 
(MARV-Mus) are attenuated and have been shown to protect rodents and 
nonhuman primates from lethal disease (Jones et al. 2005) and subsequently 
vaccine vectors for other MARV isolates and ebolavirus species have been 
developed (Marzi et al. 2011).  
Protective efficacy testing of vaccine candidates against challenge with 
filoviruses isolated directly from human or wildlife (wild-type (wt) isolates) can 
only be performed in macaques or immunocompromised rodents (i.e. STAT1-/- 
or interferon α/β receptor (IFNAR)-/- mice), where infection causes disease 
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	 without previous adaptation (Bray et al. 2001; Raymond et al. 2011). While 
STAT1-/- mice have been shown to develop lethal disease after infection with 
the majority of wt filovirus isolates (Raymond et al. 2011), IFNAR-/- mice seem 
more resistant to infection with wt filoviruses i.e. Reston virus (RESTV) (Bray 
2001). As the rVSV vector for EBOV-May did not cause disease in 
immunocompromised NOD-SCID mice (Jones et al. 2007), we sought to 
evaluate the usefulness of STAT1-/- mice as a model for the initial evaluation of 
the protective efficacy of new or improved rVSV filovirus vaccine vectors.  
We hypothesized that the attenuated rVSV vectors would also be attenuated in 
this immunocompromised mouse model, in which rVSVwt causes lethal disease 
(Katzenell et al. 2014). We found, however, that vaccination of STAT1-/- mice 
with 4 different monovalent rVSV vectors individually expressing different filovirus 
glycoproteins (GP) resulted in systemic infection with lethal outcome for most of 
the rVSV vectors. In conclusion, while STAT1-/- mice are an animal model for wt 
Ebola- and Marburgvirus infections, this animal model can likely not be utilized 
for efficacy testing of live-attenuated vaccines such as the rVSV-based vectors. 
 
  
Marceau,	Joshua	O.,	Ph.D.,	Fall	2016	 	 Department	of	Biomedical	Sciences	
36	
	 Methods 
Animal ethics and safety statements.  
 
Research was approved and conducted in compliance with the guidelines of the 
NIAID/RML Institutional Animal Care and Use Committee (IACUC). The facility 
where this research was conducted is fully accredited by the Association for the 
Assessment and Accreditation of Laboratory Animal Care International 
(AAALAC) and has an approved Office of Laboratory Animal Welfare (OLAW) 
Assurance (#A4149-01). All procedures were conducted by trained personnel 
under the supervision of veterinarians, and all invasive clinical procedures were 
performed while animals were anesthetized. Early endpoint criteria, as specified 
by the IACUC approved scoring parameters, were used to determine when 
animals should be humanely euthanized. rVSV vectors are classified as biosafety 
level 2 (BSL2) pathogens and all work with the live vectors was approved by the 
Institutional Biosafety Committee (IBC) under BSL2 conditions.  
Virus recovery, propagation and purification:  
 
The following rVSVs were recovered from full-length plasmids and propagated as 
described previously (Lawson et al. 1995; Garbutt et al. 2004; Marzi et al. 2011): 
rVSVwt, rVSV/EBOV-May-GP, rVSV/RESTV-Pen-GP (RESTV, strain 
Pennsylvania), rVSV/MARV-Mus-GP, and rVSV/MARV-Ang-GP (MARV, strain 
Angola). Viruses were subsequently purified through a 20% sucrose cushion, 
resuspended in DMEM (Sigma, St. Louis, MO) containing 10% FBS (Life 
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	 Technologies, Carlsbad, CA), aliquotted and stored at -80ºC. Viral titers were 
determined performing classical plaque assay on Vero cells (Marzi et al. 2011) 
and the median tissue culture infectious dose (TCID50) using the Reed-
Muench method (Reed et al. 1938).  
Growth kinetics.  
 
Vero E6 cells were seeded in a 24-well plate the day before the experiment. 
Infection was performed with rVSVwt, rVSV/EBOV-May-GP, rVSV/RESTV-Pen-
GP, rVSV/MARV-Mus-GP and rVSV/MARV-Ang-GP at a multiplicity of infection 
of 0.001 for one hour. Following washes with plain DMEM, cells in each well 
were covered with 1 ml DMEM/2% FBS. At time points 0, 6, 12, 24, 36, 48, 72, 
and 96 hours post infection 30 μl supernatant were collected. Samples were 
stored at -80ºC before titration on Vero E6 cells.  
Mouse experiments.  
 
Four to six week old 129S6/SvEv control and 129S6/SvEv-STAT1-/- mice 
(Harlan Laboratories) were inoculated with the indicated dose of rVSV (diluted in 
sterile DMEM) by intraperitoneal (i.p.) injection in a total volume of 200 μl. The 
animals were monitored for signs of illness and weighed daily. On necropsy 
days, mice were anesthetized, bled, euthanized and tissue samples were taken 
and stored at -80ºC. Surviving mice were euthanized 21 days after infection, and 
serum was collected for antibody titrations.  
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	 Titrations.  
 
Vero E6 cells were seeded the day before titration in 96-well plates. Tissue 
samples were homogenized in DMEM, cleared from debris by centrifugation and 
serial dilutions were prepared. Blood and cell culture supernatants were thawed 
and serial dilutions were prepared. A confluent layer of Vero E6 cells was 
infected in triplicates per dilution for one hour at 37ºC, then 100 μl DMEM/2% 
FBS were added. After 2-6 days the plates were analyzed for VSV specific 
cytopathic effect (CPE) and the median tissue culture infectious doses (TCID50) 
were calculated using the Reed-Muench method (Reed et al. 1938).  
Results & Discussion 
 
For the development of filovirus vaccines, promising candidates will require 
efficacy testing, which involves challenging immunized animals with infectious wt 
Ebola- and Marburgviruses. In the case of small rodent models, only the use of 
immunocompromised mouse strains or rodent-adapted viruses that cause severe 
disease are suitable for adequately evaluating vaccine efficacy. We sought to 
establish a mouse screening model for efficacy testing of live, attenuated 
vaccines, in which wt stocks of Ebola or Marburg virions could be used to 
challenge immunized animals. We chose STAT1-/- mice, which lack a response 
to interferon α, β and γ, and have previously been shown to be largely 
susceptible to wt filovirus infections (Raymond et al. 2011). The potential 
feasibility of this approach was supported by the self-limiting replication of the 
first rVSV filovirus vector, rVSV/EBOV-May-GP, in immunocompromised NOD-
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	 SCID mice resulting in an asymptomatic phenotype (Jones et al. 2007). In 
contrast, VSVwt infection is known to cause lethal disease in STAT1-/- mice 
(Katzenell et al. 2014), but replication of rVSV vectors expressing filovirus GPs 
instead of the VSV glycoprotein is known to be attenuated in vitro and in vivo 
(Garbutt et al. 2004; Jones et al. 2005).  
In a first experiment we compared the growth kinetics of rVSVwt, rVSV/EBOV-
May-GP, rVSV/RESTV-Pen-GP, rVSV/MARV-Ang-GP and rVSV/MARV-Mus-GP 
in Vero E6 cells over 72 hours. As expected, 3 of the 4 different rVSV vectors 
replicated similarly in cell culture and were strongly attenuated (several log10) 
compared to rVSVwt, but reached the same end titer at 72 hours. The exception 
was rVSV/MARV-Ang-GP, which was less attenuated over the same time period 
(Fig. 2-1A). This finding is surprising and further investigations need to address 
potential unique features of the MARV-Ang-GP that may influence infectivity, as 
the glycoprotein mediates virus entry and is the only difference among all 
vectors.  
We next moved on to perform in vivo characterization of the rVSV vectors. First, 
groups of 3 129S6/SvEv control mice (immunocompetent) were i.p. infected 
(usual route of rVSV vaccination in mice) with 10^7 pfu of the 4 rVSV filovirus 
vectors and rVSVwt; none of the animals developed weight loss or other signs of 
disease (data not shown). Second, groups of 3 STAT1-/- mice were i.p. infected 
with different doses (ranging from 10^4-10^7 pfu/animal) of the rVSV vectors and 
monitored daily for weight change and disease progression. As expected, 
rVSVwt caused lethal outcome in STAT1-/- mice at all doses tested (Fig. 2-1B). 
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	 Surprisingly, the only clearly attenuated vector was rVSV/MARV-Mus-GP, for 
which infection resulted in 67-100% survival (Fig. 2-1C right panel). While most 
of the mice survived, all infected animals displayed signs of disease including 
weight loss (data not shown). Interestingly, rVSV/EBOV-May-GP was only 
slightly attenuated at the two lower doses with all animals succumbing to 
infection in a dose-dependent manner (Fig. 2-1D left panel). Similarly, 
rVSV/RESTV-Pen-GP was only minimally attenuated in the groups receiving the 
two lower doses with increased time to euthanasia (Fig. 2-1D right panel). 
Interestingly, rVSV/MARV-Ang-GP was advanced in disease progression with all 
animals succumbing to infection slightly faster than rVSVwt infected mice 
independent of the dose (Fig. 2-1C left panel). 
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Figure	2-1: Wild-type	recombinant	vesicular	stomatitis	virus	(rVSVwt)	and	
rVSV	filovirus	vaccines	replicate	comparably	in	vitro	and	can	cause	lethal	
infection	in	Stat1−/−	mice. 	
A, In vitro growth kinetics on Vero E6 cells. Infection with a multiplicity of infection 
of 0.001 resulted in the depicted growth curves for rVSVwt (black circle on a 
black solid line), rVSV/EBOV-May-GP (Ebola virus strain Mayinga; black square 
on a black dotted line), rVSV/RESTV-Pen-GP (Reston virus strain Pennsylvania; 
grey circle on a grey solid line), rVSV/MARV-Ang-GP (Marburg virus strain 
Angola; black solid diamond on a black dotted line), and rVSV/MARV-Mus-GP 
(Marburg virus strain Musoke; black diamond on a black solid line). B–D, Groups 
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	 of 3 mice were infected with the indicated vector and monitored daily for weight 
loss and signs of illness. Survival curves are shown. Abbreviations: PFU, 
plaque-forming units; TCID50, 50% tissue culture infectious dose. 
 
All surviving immunocompetent control and STAT-1 knockout mice were 
euthanized on day 21 after infection and serum was collected for the analysis of 
humoral immune responses. Every animal seroconverted to VSV with titers 
≥102,400 confirming that all mice were indeed infected with rVSV (data not 
shown). In addition, we compared GP-specific IgG responses in rVSV/MARV-
Mus-GP infections of immunocompetent control and STAT1-/- mice, which 
developed IgG titers up to 25,600 and 6,400, respectively (data not shown). The 
lower titers detected in STAT1-/- mice are not unexpected, as these animals are 
defective in cell signaling pathways that contribute to T- and B-cell responses. In 
macaques, however, a MARV-Mus-GP-specific IgG titer of 640 has been 
sufficient for protection against lethal MARV-Mus challenge (Jones et al. 2005; 
Mire et al. 2014), suggesting that the rVSV-immunized STAT1-/- mice might be 
protected from lethal filovirus challenge. 
While it became obvious that STAT1-/- mice are not an appropriate model 
for testing protective efficacy of rVSV filovirus vectors, we sought to characterize 
the disease caused by all the rVSV vectors in these mice. In order to determine 
the tissue tropism and organ virus load, we infected groups of 10 STAT1-/- mice 
with 10^7 pfu of the different rVSV vectors and euthanized 5 animals each at 12 
and 24 hours post inoculation. At the time of euthanasia, blood, lymph node, 
lung, heart, liver, spleen, kidney, and brain samples were collected and frozen for 
virus titration. As expected, the highest virus loads in all tissues were obtained for 
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	 rVSVwt infected animals with titers comparable to previously published data 
from VSV infected STAT1-/- or IFNAR-/- mice (Katzenell et al. 2014; Honke et 
al. 2012). Notably, the lowest amounts of rVSVwt were consistently found in the 
brain of all mice (Fig. 2-2A). Viremia and tissue titers were comparable for 
rVSVwt and rVSV/MARV-Ang-GP infected mice at both time points (Fig. 2-2A, B 
left panel), confirming systemic infection and similar disease progression (Fig. 2-
1B, C right panel). The only notable difference was found for brain tissue, in 
which rVSV/MARV-Ang-GP could only be detected in 1/5 mice at each time point 
(Fig. 2-2B left panel). 
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Figure	2-2: Recombinant	vesicular	stomatitis	virus	(rVSV)	vectors	replicate	
systemically	in	Stat1−/−	mice. 	
Groups of 5 mice were infected with 10^7 plaque- forming units of the respective 
rVSV vector and euthanized at the indicated time points. Tissue samples were 
collected, and virus titers were determined. The organ loads of rVSVwt (wild-type 
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	 rVSV; A), rVSV/MARV-Ang-GP (Marburg virus strain Angola; B, left panel), 
rVSV/MARV-Mus-GP (Marburg virus strain Musoke; B, right panel), 
rVSV/EBOV-May-GP (Ebola virus strain Mayinga; C, left panel), and 
rVSV/RESTV-Pen-GP (Reston virus strain Pennsylvania; C, right panel) per 
group are shown. Error bars represent standard errors of the mean. 
Abbreviation: TCID50, 50% tissue culture infectious dose. 
 
Slightly lower virus titers were detected in blood and tissues of rVSV/EBOV-May-
GP infected mice (Fig. 2-2C left panel), mirroring the slightly slower disease 
progression compared to rVSVwt and rVSV/MARV-Ang-GP infected animals 
(Fig. 2-1B, C left panel, D left panel). As noted with rVSV/MARV-Ang-GP infected 
animals, rVSV/EBOV-May-GP was only found to replicate in the brain of 1 mouse 
(Fig. 2C left panel). Infection of STAT1-/- mice with rVSV/RESTV-Pen-GP resulted 
in viremia similar to animals infected with rVSV/EBOV-May-GP, but virus tissue 
loads were lower and only detectable in liver, spleen and lymph node (Fig. 2-2C 
right panel). This finding is in contrast to the lethal phenotype in STAT1-/- mice 
(Fig. 2-1C right panel) and warrants further investigation. rVSV/MARV-Mus-GP 
infection resulted in the lowest viremia and in reduced viral tissue loads of all 
rVSV vectors (Fig. 2-2B right panel), which is in line with the attenuation of this 
vector (Fig. 1D right panel), but it still caused systemic infection without reaching 
the brain.  
Notably, rVSV infected immunocompetent control mice did not show any 
signs of disease and virus was only occasionally isolated from lymph nodes, liver 
or spleen samples of mice infected with any of the rVSV vectors including 
rVSVwt. Overall, infection of immunocompetent control mice did not result in 
productive rVSV replication, but was sufficient to generate humoral immune 
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	 responses (discussed above). For rVSV/EBOV-May-GP these antibody 
responses have previously been shown to protect mice from lethal mouse-
adapted EBOV challenge (Jones et al. 2007).  
While immunocompetent mice do not develop disease after infection with 
wt Ebola- and Marburgviruses, it has been shown that STAT1-/- mice are 
susceptible to infection with these pathogens leading to uniform lethality (Bray 
2001; Raymond et al. 2011). Although kinetics of disease progression differed 
among wt filoviruses, replication was similar for all with key target organs being 
lymph nodes, liver and spleen (Raymond et al. 2011). Overall, organ tropism of 
the rVSV filovirus vaccine vectors studied here in STAT1-/- mice was similar and 
confirms a key role of GP in determining cell and tissue tropism (Feldmann et al. 
2013). Interestingly, also the organ tropism of rVSVwt was similar (Katzenell et 
al. 2014; Honke et al. 2012), which may be explained by the in general systemic 
nature of infections in STAT1-/- mice caused by wt filoviruses, rVSV filovirus 
vaccine vectors and VSVwt. The only exception was the brain, which seems to 
be only a major target organ of VSVwt infection. 
While STAT1-/- mice are not an appropriate animal model for evaluating 
the protective efficacy of live-attenuated vectors such as the rVSV filovirus 
vaccines, this animal model might be useful for further studies characterizing the 
function of filovirus GPs. The remarkably different phenotypes displayed by the 
two rVSV/marburgvirus-GP and the two rVSV/ebolavirus-GP vectors in STAT1-/- 
mice are likely caused by different properties of their GPs, warranting further 
investigations.   
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	 CHAPTER 3 EVALUATION OF POST-EXPOSURE PROTECTION 
CONFERRED BY VESICULAR STOMATITIS VIRUS-BASED VACCINES.  
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	 Introduction 
 
Hantaviruses are a group of zoonotic pathogens comprising the genus 
Hantavirus within the Bunyaviridae family. They are enveloped particles 
containing a tri-segmented, single stranded, negative sense RNA genome. The 
three viral RNA segments are designated small (S), medium (M) and large (L) 
and encode the nucleocapsid protein (NP), the glycoprotein precursor (GPC) and 
the viral RNA polymerase (RdRp), respectively (Löber et al. 2001). Hantavirus 
are rodent or insectivore-borne pathogens and primary transmission to humans 
is thought to largely occur by inhalation of dried excreta (Jonsson et al. 2010). 
Hantavirus infections in humans are associated with two clinical syndromes; 
hemorrhagic fever with renal syndrome (HFRS) and hantavirus 
(cardio)pulmonary syndrome (HCPS or here HPS), which are caused by Old 
World  and New World hantaviruses, respectively (Clement et al. 2014). Of the 
22 described human-pathogenic hantaviruses, Andes virus (ANDV) is one of the 
most virulent New World hantaviruses (Schonrich et al. 2015). ANDV has a HPS 
case fatality rate of >40% and is the only reported hantavirus that is known to 
transmit directly from human–to–human (Martinez-Valdebenito et al. 2014). 
Therefore, among all New World hantaviruses a vaccine would be of particular 
interest for ANDV, for which a hamster disease model has been established 
(Hooper et al. 2001). 
In a previous study we have demonstrated the potency of a live-attenuated, 
recombinant vesicular stomatitis virus (rVSV)-based vaccine vector expressing 
the ANDV glycoprotein precursor in place of the VSV glycoprotein (rVSVΔG-
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	 ANDVgpc) with complete and partial (90%) protection in the Syrian Golden 
hamsters against lethal ANDV challenge when administered as close as 3 days 
prior to and 24 hours post infection, respectively (Brown et al. 2011). 
Surprisingly, a similar rVSV vaccine vector expressing the Ebola virus 
glycoprotein (rVSVΔG-ZEBOVgp), used as a negative control, also mediated 
partial protection against lethal ANDV challenge when administered between 7 
days prior to 3 days post infection (Brown et al. 2011). Detection of strong 
induction of innate immune responses, particularly through rVSVΔG-ZEBOVgp 
(Brown et al. 2011), lead to the hypothesis that a bivalent vector expressing 
ANDV GPC on the backbone of rVSVΔG-ZEBOVgp) would be a more potent 
ANDV vaccine.  
In this study we investigated the protective efficacy of two monovalent 
(rVSVΔG-ANDVgpc and rVSVΔG-ZEBOVgp) and two bivalent rVSV vaccine 
vectors (rVSVΔG-ANDVgpc-ZEBOVgp (Tsuda et al. 2011) and rVSVΔG- 
ZEBOVgp-ANDVgpc (this study)) in hamsters against lethal ANDV challenge. In 
addition, two routes of immunization, intraperitoneal and intranasal, were 
compared. The two bivalent vectors both mediated full protection when 
administered even 3 days prior to ANDV challenge independent of the route of 
immunization. The monovalent rVSVΔG-ANDVgpc was similarly protective but 
intranasal immunization showed reduced efficacy when administered close to 
challenge. The bivalent rVSVΔG-ZEBOVgp-ANDVgpc was most potent in post-
exposure treatment, followed by the monovalent rVSVΔG-ZEBOVgp. The 
monovalent rVSVΔG-ANDVgpc was least potent in post-exposure treatment. 
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	 Intraperitoneal immunization was superior over the intranasal route in post-
exposure treatment. Our data indicates the benefit of bivalent rVSV vaccine 
vectors based on the rVSVΔG-ZEBOVgp backbone with the second 
immunogen expressed in the downstream position in peri-exposure application. 
 
Materials and Methods 
 
Cells and Viruses: 
 
Vero E6 (African green monkey kidney) and HEK 293T (human embryonic 
kidney) cells were maintained in Dulbecco's Modified Eagle's Medium (DMEM) 
supplemented with 10% FBS, 1% L-Glutamine, penicillin/streptomycin. BHK-21 
cells were maintained in Gibco Minimum Essential Media (MEM) supplemented 
with 10% FBS, 1% L-Glutamine, penicillin/streptomycin . ANDV, strain Chile 
9717869 (Meissner et al. 2001) (kindly provided by C. Schmaljohn, U.S. Army 
Medical Research Institute of Infectious Diseases, Fort Detrick, MD), was grown 
and titrated in Vero E6 cells as previously described (Safronetz et al. 2009). 
 
Generation of rVSV Vectors: 
 
The generation, growth and titration of rVSVs expressing the Ebola virus 
glycoprotein (rVSVΔG-ZEBOVgp), the ANDV glycoprotein precursor (rVSVΔG-
ANDVgpc) or both (rVSVΔG-ANDVgpc-ZEBOVgp) has been described 
elsewhere (Garbutt et al. 2004, Brown et al. 2011; Tsuda et al. 2011). For the 
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	 generation of rVSVΔG-ZEBOVgp-ANDVgpc), the open reading frame of the 
ANDV glycoprotein gene was amplified by iProof High-Fidelity DNA 
Polymerase (Bio-Rad) from plasmid DNA using the primers 5'-
GTAGTCGACCACCATGGAAGGGTGGTATCTGGTTGCTCTTGG-3’ 
(Sal1restriction site underlined) and 5'- 
TACGCTAGCTACCTATTAGACAGTTTTCTTGTGTCCTCTCCTGGG-3' (Nhe1 
restriction site underlined). The PCR product was digested with Xhol & Nhel, 
purified using a PCR purification kit (Qiagen) and cloned into the pATX-VSVΔG-
ZEBOVgp plasmid downstream of the ZEBOVgp ORF (Garbutt et al. 2004). The 
resulting plasmid, pATX-VSVΔG-ZEBOVgp-ANDVgpc, was sequence-confirmed 
prior to use. rVSVΔG-ZEBOVgp-ANDVgpc was rescued as described previously 
(Garbutt et al. 2004). Briefly, Vero E6 and 293T cells were seeded together into 
six-well plates at 1:6 and 1:4 dilutions, respectively. When the co-cultures 
reached 90% confluence, cells were transfected with pATX-VSVΔG-ZEBOVgp-
ANDVgpc (2µg) along with the VSV helper plasmids [SV-T7 (2.5µg), VSV-N 
(0.5µg), VSV-L (0.25µg plasmid DNA), VSV-P (1.25µg), and pCAGGS-VSVG 
(2µg)] using Lipofectamine 2000 transfection reagent (Invitrogen) and incubated 
for 24 hours at 37⁰C (5% CO2). DMEM supplemented with 3% FBS, L-Glutamine, 
penicillin/streptomycin (1ml/well) was added 24 hours after transfection. Every 12 
hours, 20% of the medium was replaced to maintain the co-culture until 
cytopathic effects (CPE) was observed 12-14 days post-transfection. 
Supernatant (500µl) of CPE-positive cells was removed and placed onto fresh 
Vero cells for an additional passage of the rescued rVSV. Supernatant was 
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	 collected from both, the transfected co-culture and blind passage on fresh Vero 
cells, to verify virus rescue by immunoblot (rVSV proteins) and RT-PCR (rVSV 
genome) as described previously (Brown et al. 2011; Tsuda et al. 2011). 
In vitro growth studies (Tissue Culture Infectious Dose 50 (TCID50) assay): 
 
Vero cells were grown to 90% confluence and triplicates were inoculated 
with rVSVs at an MOI of 0.1 and 0.001 for 1 hour at 37°C. Subsequently, the 
inoculum was replaced with fresh DMEM supplemented with 3% fetal bovine 
serum. At predetermined time points 250µl supernatant was collected from each 
of the triplicate wells and frozen at -80°C. For titration, samples were serially 
diluted ten-fold and the dilutions were used to inoculate 90% confluent Vero cells 
(triplicates) for 1 hour at 37°C. Subsequently, the inoculum was removed and 
replaced with fresh DMEM supplemented with 3% fetal bovine serum. After 4 
days if incubation at 37°C wells were analyzed by light microscopy for CPE. The 
resulting TCID50 values were calculated using the Reed-Muench method. 
rVSV pathogenesis studies: 
 
Syrian Golden hamsters (female, 4-6 weeks of age; Charles River) were 
anesthetized and inoculated intraperitoneally (i.p.) with either culture medium 
(DMEM) (Mock control) or 1x10^5 plaque forming units (pfu)  of the different 
rVSV vectors [rVSV∆G-ANDVgpc, rVSV∆G-ZEBOVgp, rVSV∆G-ANDVgpc-
ZEBOVgp, rVSV∆G-ZEBOVgp-ANDVgpc, and VSV-wt] (8 animals per group). 
Four animals per group were euthanized on day 2 post infection for collection of 
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	 blood and tissues (e.g., spleen, liver, lung, kidney, brain) to determine viral 
growth. The remaining animals (4 hamsters per group) were monitored for 
disease progression until 14 days post-infection. 
Vaccine efficacy studies: 
 
Syrian Golden hamsters (female, 5-6 weeks of age, Charles River) were 
challenged i.p. with a lethal dose of ANDV (200 focus forming units (ffu)) 
following vaccination or prior to treatment with rVSV vectors (1x10^5 pfu) by the 
i.p. or intranasal (i.n.) route. Three animals per group (9 animals in total) were 
euthanized on day 8 post-infection and blood and organ samples were collected 
for virology. The remaining six animals per group were monitored for survival for 
up to 40 days post challenge. For the post-exposure experiment a group of 
DMEM alone treated hamsters was included as a negative control group. 
Ethics and safety: 
 
Animal studies were approved by the Institutional Animal Care and Use 
Committee (IACUC) at Rocky Mountain Laboratories (RML). RML is an American 
Association for Accreditation of Laboratory Animal Care (AAALAC) approved 
facility. This study was performed in accordance with the recommendations 
described in the Guide for the Care and Use of Laboratory Animals of the 
National Institute of Health, the Office of Animal Welfare, and the United States 
Department of Agriculture. Trained personnel carried out all procedures under 
isoflurane anesthesia. The Institutional Biosafety Committee (IBC) at RML 
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	 approved all standard operating protocols (SOPs) for work with infectious rVSV 
and ANDV. 
Statistical analysis: 
 
Group numbers were selected to achieve a statistical significance with a 
minimum statistical power of 80%. All tests were one-tail tests at 95% confidence 
intervals and took into account the possibility of having unexpected survivors or 
mortality in the treated or control groups (www.dssresearch.com). 
Results 
rVSV rescue: 
The bivalent vaccine vector rVSVΔG-ZEBOVgp-ANDVgpc was rescued in 
this study using the rVSV reverse genetics system as previously established 
(Lawson et al. 1995; Garbutt et al. 2004). For this, the ZEBOVgp and ANDVgpc 
open reading frames were amplified and cloned into the pATX plasmid 
downstream of the M gene in the first (bp 3093-31625'; MluI and 3' AvrII 
restriction sites) and second cloning positions (bp 3217-3231; 5' SalI and a 3' 
NheI restriction sites) (Figure 3-1A). The resulting genome plasmid pATX-
rVSVΔG-ZEBOVgp-ANDVgpc was sequence-confirmed and used to rescue the 
corresponding rVSV on a mixture of Vero and 293 cells. Cell cultures exhibited 
CPE after 12 to 14 days post-transfection indicating successful rescue of 
rVSVΔG-ZEBOVgp-ANDVgpc. Further confirmation was obtained by RT-PCR-
amplification of the ZEBOVgp and ANDVgpc open reading frames (Figure 1B) 
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	 and by immunoblot using ZEBOVgp and ANDVgpc-specific antibodies on 
material derived from cell culture supernatants (Figure 3-1C). A virus seed 
stock was prepared by infecting Vero cells yielding a titer of 4x10^6 plaque 
forming units (pfu) as determined by standard plaque assay. The seed stock was 
sequenced for final confirmation to exclude the appearance of mutations during 
rescue and cell culture passage.  
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Figure	3-1:	Rescue	and	confirmation	of	gene	expression	of	rVSV∆G-ZEBOVgp-
ANDVgpc. 	
(A) rVSV vectors that express either monovalent [ANDV glycoprotein precursor 
(rVSV∆G-ANDVgpc) or Zaire ebolavirus glycoprotein (rVSV∆G-ZEBOVgp)] or 
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	 bivalent (ANDV and ZEBOV glycoproteins; rVSV∆G-ZEBOVgp-ANDVgpc; 
rVSV∆G-ANDVgpc-ZEBOVgp) immunogens in place of the native VSV 
glycoprotein (VSVwt). (B) RT-PCR amplification of a part of the ZEBOVgp and 
ANDVgpc open reading frames from rescued rVSV∆G-ZEBOVgp-ANDVgpc. 
(C) Immunoblot using ZEBOVgp and ANDVgpc-specific antibodies on material 
derived from cell culture supernatants infected with rVSV∆G-ZEBOVgp-
ANDVgpc. 
rVSVs are attenuated in vitro: 
As our in vivo vaccine efficacy model is the Syrian Golden hamster, in 
vitro testing was started in BHK cells. For this, BHK-21 cells were infected with 
rVSVΔG-ZEBOVgp-ANDVgpc, rVSVΔG-ANDVgpc-ZEBOVgp, rVSVΔG-
ZEBOVgp, rVSVΔG-ANDVgpc, or VSVwt at an MOI of 0.001 and supernatants 
were collected over the course of 65 hours. VSVwt replicated to the highest titers 
at all time points of the experiments with >4 log differences to any rVSV within 
the first 24 hours (Figure 3-2A). Up to 24 hours post infection the rVSVs showed 
minor differences in replication kinetics with the bivalent vector rVSVΔG-
ANDVgpc-ZEBOVgp displaying the lowest replication rate. After 24 hours, all of 
the rVSVs showed comparable virus growth kinetics reaching similar endpoint 
titers at 65 hours post infection, about 1 log lower compared to VSVwt (Figure 3-
2A). Virus growth kinetics for all rVSVs were also performed in Vero cells in 
comparison to VSVwt resulting in similar replication kinetics (data not shown). 
Altogether, the introduction of the foreign glycoprotein genes into the rVSV∆G 
genome resulted in in vitro attenuation of the resulting vectors without major 
differences between monovalent and bivalent vectors. 
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Figure	3-2:	rVSVs are attenuated in cell culture and in the hamster disease  
model compared to VSVwt. 	
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	 (A) BHK-21 cells were infected with rVSVΔG-ZEBOVgp-ANDVgpc, rVSVΔG-
ANDVgpc-ZEBOVgp, rVSVΔG-ZEBOVgp, rVSVΔG-ANDVgpc, or VSVwt at an 
MOI of 0.001 and supernatants were collected over the course of 65 hours. 
Supernatants were analyzed using a TCID50 assay. (B) Hamsters (groups of 8 
animals) were inoculated i.p. with a single dose of rVSV∆G-ANDVgpc, 
rVSV∆G-ZEBOVgp, rVSV∆G-ZEBOVgp-ANDVgpc, rVSV∆G-ANDVgpc-
ZEBOVgp or VSVwt (10^5 PFU/animal). Blood and tissue samples (brain, liver, 
lung, kidney, and spleen) were taken from 4 hamsters in each group 2 days after 
inoculation and infectious titers were analyzed using a TCID50 assay. DMEM-
inoculated animals served as non-inoculated controls. (C) The remaining 4 
animals of each group were monitored for survival over the course of 14 days. 
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	 rVSV vectors are in vivo attenuated: 
Syrian Golden hamsters (groups of 8 animals) were inoculated i.p. with a 
single dose of rVSV∆G-ANDVgpc, rVSV∆G-ZEBOVgp, rVSV∆G-ZEBOVgp-
ANDVgpc, rVSV∆G-ANDVgpc-ZEBOVgp and VSVwt (10^5 PFU/animal). A 
DMEM-inoculated animals served as non-inoculated controls. The inoculation 
with VSVwt at this dose resulted in lethality of 50%. In contrast, animals in all 
other rVSV inoculated groups showed no or very limited disease signs 
(temporary minor weight loss of up to 3% over the first three days) and survived 
the inoculation (Figure 3-2C). To assess rVSV replication, blood and tissue 
samples (brain, liver, lung, kidney, and spleen) were taken from 4 hamsters in 
each group 2 days after inoculation and infectious titers were analyzed using a 
TCID50 assay (Figure 3-2B). VSVwt inoculated animals were positive in all 
tissues tested. To assess survival after rVSV inoculation the remaining 4 
hamsters in each group were monitored for symptoms of disease such as weight 
loss, ruffled fur, reduced movement, and others for 14 consecutive days or until 
clinical signs indicated a humane endpoint (Figure 3-2C). Of all rVSV groups only 
animals inoculated with rVSV∆G-ZEBOVgp were clearly positive for viral 
infectivity with organ titers similar to VSVwt inoculated animals. Organ titers 
around the detection limit were found in hamsters inoculated with rVSV∆G-
ZEBOVgp-ANDVgpc, whereas no viral infectivity was found in organs or blood of 
animals inoculated with rVSV∆G-ANDVgpc or rVSV∆G-ANDVgpc-ZEBOVgp 
(Figure 3-2B). Overall, all rVSV vectors are attenuated in the hamster disease 
model compared to VSVwt warranting vaccine efficacy studies in this model.   
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	 rVSV vectors protect against ANDV challenge when administered pre-
exposure.  
For pre-exposure efficacy testing of the rVSV vectors, hamsters (group of 9 
animals) were immunized i.p. or i.n. with a single dose of 10^5 PFU 28 days 
before lethal ANDV challenge (200 FFU/animal). Three animals of each group 
were euthanized on day 8 post challenge for lung (main target organ for ANDV 
infection) and blood titration. All animals remained clinically asymptomatic during 
the vaccination period indicating a lack of adverse effects to immunization with 
the rVSV vectors in this animal species. The animals immunized with the 
monovalent non-specific rVSVΔG-ZEBOVgp vector, expressing the ZEBOV 
glycoprotein were, as expected, unprotected and succumbed to infection 
between days 7 to 11 post ANDV challenge (Table 3-1). Animals immunized with 
the monovalent specific rVSVΔG-ANDVgpc vector were expected to be protected 
and showed 100% (i.n. vaccination) and 83% (i.p. vaccination) survival. Animals 
immunized with the two bivalent vectors, rVSVΔG-ZEBOVgp-ANDVgpc and 
rVSVΔG-ANDVgpc-ZEBOVgp were completely protected independent of route of 
vaccination. The survival data is supported by organ and blood titers as shown in 
Figure 3-3A. 
 
Marceau,	Joshua	O.,	Ph.D.,	Fall	2016	 	 Department	of	Biomedical	Sciences	
64	
	
 
 
Table 3-1: Bivalent rVSV∆G-ZEBOVgp-ANDVgpc offers better post-exposure 
protection than previous bivalent and monovalent constructs. 
Hamsters (group of 6 animals) were immunized i.p. or i.n. with a single dose of 
10^5 PFU before (-28 days and -3 days pre-exposure) or after (days +1, +3 and 
+5 post-exposure) lethal ANDV challenge (200 FFU/animal). Animals were 
monitored for survival up to 40 days post challenge.  
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	 In order to address the potential for rapid immunization we next 
immunized animals with a single dose of 10^5 PFU 3 days prior to lethal ANDV 
challenge (200 FFU/animal). Animals immunized by the i.n. route with the 
monovalent specific rVSVΔG-ANDVgpc vector were only partially protected 
(33%), whereas animals immunized i.p. showed full protection (100%) (Table 1). 
Interestingly, survival increased from none to 33% in the group that was 
immunized i.p. with the non-specific monovalent rVSVΔG-ZEBOVgp vector 
(Table 3-1). All animals immunized by either route with the two bivalent vectors 
were fully protected against lethal ANDV challenge. As with the day 28 
immunization, the survival data is supported by organ and blood titers shown in 
Figure 3-3B. 
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	 Figure	3-3: Blood and lung tissue data support survival data in pre-
exposure treatment with rVSVs.	
Hamsters (group of 9 animals) were immunized i.p. or i.n. with a single dose of 
10^5 PFU before (-28 days and -3 days) lethal ANDV challenge (200 
FFU/animal). (A) lung tissue and blood was taken from 3 animals of each group 
vaccinated 28 days prior to challenge and analyzed for viral replication using RT-
PCR. (B) Lung tissue and blood were taken from 3 animals of each group 
vaccinated 3 days prior to challenge and analyzed for viral replication using RT-
PCR. 
rVSV vectors protect against ANDV challenge when administered shortly after 
exposure: 
For post-exposure efficacy testing of the rVSV vectors, hamsters (group of 
9 animals) were immunized i.p. or i.n. with a single dose of 10^5 PFU on days 
+1, +3 and +5 after lethal ANDV challenge (200 FFU/animal). As with the pre-
exposure study, three animals of each group were euthanized on day 8 post 
challenge for organ (lung) and blood titration. None of the animals immunized i.p. 
or i.n. on day 5 or immunized i.n. on day 3 post ANDV challenge were protected. 
Disease progression was almost identical to DMEM-treated controls resulting in 
death (Table 3-1). In contrast, all hamsters in the groups immunized i.p. 1 day 
post ANDV challenge with the two bivalent vectors as well as the non-specific 
monovalent rVSVΔG-ZEBOVgp vector survived ANDV challenge, whereas 
surprisingly survival was only 33% in the group immunized i.p. with the 
monovalent rVSVΔG-ANDVgpc vector (Table 3-1). The i.n. route of immunization 
was less efficient but showed a similar trend with only the hamsters in the 
rVSVΔG-ZEBOVgp-ANDVgpc group showing 100% survival, followed by 83% 
and 50% survival when immunized i.n. with rVSVΔG-ZEBOVgp and rVSVΔG-
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	 ANDVgpc-ZEBOVgp, respectively. Again, the monovalent specific rVSVΔG-
ANDVgpc vector did not perform well with no survival after single-shot i.n. 
immunization. A similar result was observed with i.p. immunization on day 3 
post ANDV challenge. The bivalent rVSVΔG-ZEBOVgp-ANDVgpc vector 
performed best with 83% survival followed by the rVSVΔG-ZEBOVgp vector with 
67% survival. The other two vectors did not provide any protection from disease 
and death. Infectivity data on lung tissue and blood confirmed ANDV infection of 
the animals, but did not show significant distinction among the vaccine groups 
(Figure 3-4). 
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	 Figure	3-4:	Post-exposure	treatment	with	rVSVs	does	not	prevent	ANDV	
Infection. 	
Hamsters (group of 9 animals) were immunized i.p. or i.n. with a single dose of 
10^5 PFU after lethal ANDV challenge (200 FFU/animal). (A) Three animals of 
each group inoculated 1 day after challenge were euthanized on day 8 post 
challenge for organ (lung) and blood titration using RT-PCR. This was repeated 
for groups inoculated 3 days (B) and 5 days (C) after challenge. 
 Overall, best performance in post-exposure vaccination was achieved 
with the two bivalent vectors with rVSVΔG-ZEBOVgp-ANDVgpc being superior in 
efficacy. Interestingly, the monovalent non-specific rVSVΔG-ZEBOVgp vector 
was almost as efficacious against ANDV challenge if administered shortly after 
post-exposure. Surprisingly, the monovalent specific rVSVΔG-ANDVgpc vector 
performed extremely poorly in post-exposure vaccination. The i.p. immunization 
route was superior over the i.n. route for post-exposure vaccination. 
Discussion 
Although the annual cases of ANDV remain low in South America when 
compared to incidences of Old World strains in Europe and Asia, the high 
lethality rate and the potential for human-to-human transmission illustrates that a 
vaccine and other treatments for the disease need to be developed.  
Historically, rVSV has been used extensively as a laboratory tool for 
studying virus and cell biology, but more recently its potential as a therapeutic 
and vaccine tool has been realized. Here we have constructed and rescued a 
bivalent rVSV vaccine vector that expresses the glycoproteins from ZEBOV and 
ANDV in place of the native VSV glycoprotein. The rationale for the bivalent 
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	 vaccine vector was based on evidence that the ZEBOVgp targets the vaccine 
vectors to important immune cells strongly enhancing innate immune 
responses (Prescott et al. 2015). For this study we used the Syrian hamster 
model to test vaccine safety and efficacy. While rVSVwt caused systemic 
infection in Syrian hamsters resulting in severe or lethal outcome, the rVSV-
based vaccine candidates temporarily replicated in Syrian hamsters without 
causing signs of clinical disease.  We showed that the rVSV-based vaccine 
candidates are attenuated when compared to the VSVwt in hamsters and tissue 
culture cells.  
The protective efficacy of the rVSV vectors was also tested following 
administration prior to or after ANDV challenge in the HPS hamster model in 
order to define the most potent candidate vaccine for prophylactic vaccination 
and post-exposure treatment. The results indicated that the organization of the 
ZEBOV and ANDV genes can alter the protection in the hamster. Importantly, the 
efficacy of post-exposure protection was increased by including the ZEBOVgp 
upstream of the ANDVgpc immunogen in the bivalent rVSV∆G-ZEBOVgp-
ANDVgpc. This may be due to increased ZEBOVgp production, expression or 
presentation to the innate immune system. 
Although ANDV results in systemic infection in hamsters, the lungs are the 
primary site of viral replication and the only organ which develops pathological 
abnormalities during the course of disease (Safronetz et al. 2011). We correctly 
expected that, similar to i.p. immunization, administration of the ANDVgpc 
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	 containing rVSV vaccines via the i.n. route would provide 100% protection 
when given 28 days pre-exposure. While we hypothesized that i.n. 
immunization would provide increase post-exposure protection by eliciting a 
strong innate immune response directly in the lungs of hamsters, the results 
showed a trend that indicated that the i.p. route was more effective and that the 
efficacy of mucosal immunization post-challenge may not offer the same 
protection as a systemic i.p. inoculation.   
The results of these experiments further defined the protective efficacy of 
the recombinant rVSV vaccine candidates in the Syrian hamster model when 
challenged with a lethal dose of ANDV. Importantly, using the novel rVSV vectors 
we were able to demonstrate an increase in efficacy of post-exposure protection 
in the lethal hamsters model of HPS (Brown et al. 2011; Tsuda et al. 2011).  
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CHAPTER 4 CONCLUSIONS 
Summary 
 
Although the annual cases of ANDV remains low in South America, when 
compared to incidences of Old World strains of Europe and Asia, the high 
lethality rate and the potential for human-to-human transmission illustrates that a 
vaccine and other treatments for the disease need to be developed. This 
dissertation describes the development of a rVSV based vaccine platform that is 
effective in protecting Syrian hamsters in peri-exposure challenge with a lethal 
dose of ANDV. In addition, constructs that contain the ANDVgpc are also useful 
when used as a conventional vaccine 28 days before challenge.  
In summary, these data have shown that rVSV presents an efficient 
system for tailoring specific vaccines for ANDV. First, chapter 2 investigates the 
use of STAT1 KO mice as an animal model to test the tolerance of rVSV 
constructs as vaccine vectors. The results of chapter 2 have shown that mice 
lacking an innate immune response involving interferon alpha, beta, and gamma 
do not comprise an animal model which is suited for testing rVSV vaccine 
vectors. Specifically, the rVSVs cause severe disease in the 
immunocompromised mouse model therefore disqualifying it as a useful model in 
my studies. Second, chapter 3 describes the successful design and rescue of a 
bivalent rVSV that expresses both ANDV and ZEBOV glycoproteins in place of 
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	 the deleted VSV glycoprotein. The results in chapter 3 describe how the 
insertion of glycoproteins from ZEBOV and ANDV effectively attenuates the 
pathogenicity of the rVSV vector thereby reducing negative symptoms in the 
hamster model while still allowing enough replication for the rVSVs to induce a 
robust and protective immune response after only one inoculating dose. The data 
support that the rVSV∆G-ZEBOVgp-ANDVgpc vaccine vector was more 
protective than both monovalent vectors and the bivalent vector rVSV∆G-
ANDVgpc-ZEBOVgp. The new bivalent vector rVSV∆G-ZEBOVgp-ANDVgpc  
was able to protect 83% of animals with a single i.p. inoculation 3 days after a 
lethal ANDV challenge. This surpasses all other previously developed rVSV 
vaccines designed for hantavirus vaccination in the Syrian hamster model. The 
protections studies show that, for overall survival, the bivalent vectors with both 
the ZEBOV and ANDV glycoprotein inserts are very effective. It may be shown in 
future studies that look more closely at the specific immune response that the 
ZEBOVgp is effective at initiating a broadly protective short term innate response 
while the presence of the ANDVgpc allows the formation/establishment of a long 
lived and specific adaptive response in a single dose immunization. The survival 
results of these protection studies also suggest that the placement of the 
glycoprotein gene in the rVSV genome can play a significant role in the survival 
outcome of lethally inoculated animals. In general, having the ZEBOVgp gene in 
the most upstream cloning position was more protective in the post-exposure 
vaccination when animals were challenged with a lethal dose of ANDV in both 
the monovalent and bivalent genome configurations. The data showing the viral 
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	 load on blood and lung from lethally inoculated animals is interesting but 
difficult to make any conclusions about without more in-depth experiments that 
examine the mechanism of the immune response. It may indicate that survival 
may not be as dependent on the ability of the rVSV vector to induce an immune 
state that reduces the overall viral load (in post exposure studies) but may be 
another mechanism that is more influential in survival. This may be due to the 
vector's ability to modulate the immune response to reduce pathological and 
destructive immune responses. One of the limitations of these studies is the lack 
of established and commercially available reagents to examine the mechanism of 
the hamster immune response but, as the hamster model sees increased use as 
a disease model these materials will become more available.  
 In light that rVSV constructs, which contain an unrelated antigen to the 
hantavirus family, can provide protection against a heterologous virus challenge 
is striking. It has been hypothesized that rVSV is able to produce a very robust, 
non-specific, innate response which serves to suppress the levels of the 
challenge virus until the adaptive immune response, which would otherwise be 
too slow, establishes itself enough to clear the virus. 
Significance 
 
These studies have the potential to further the understanding of vaccine 
action and may provide insights that lead to the development of better vaccines 
that are fast acting, are effective without multiple boosts and can offer protection 
in extremely short durations before exposure. Such scenarios could be critical in 
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	 an ANDV outbreak where human-to-human transmission has been 
documented, as well as, post exposure treatments that could arise in the field 
or in laboratory conditions. The ability to administer a vaccination that can 
protect in the extreme short term and after exposure have proved to be extremely 
useful. Examples of this can be found in the current Rabies vaccine and the use 
of the experimental rVSV-ZEBOV vaccine in the recent West African Ebola 
outbreak where a VSV-based vaccine was successfully used in emergency ring 
vaccination. (Henao-Restrepo et al. 2016) (Dean et al. 2015). I anticipate that this 
research will provide useful insight that allows the future development of these 
types of vaccines and reduce the number of deaths that result from these ever 
increasing and dangerous zoonotic pathogens as our world becomes less 
constrained by borders and more mobile.  
Future Directions 
 
In conclusion of my research project, I have gathered data that will 
generate renewed and lasting interest in the phenomenon that allows the 
ZEBOVgp to protect against unrelated viral diseases when used as a peri-
exposure vaccination. In particular it will be interesting what insights will be 
discovered regarding the mechanism of the immune response as newer more 
powerful tools become available. For future directions the mechanism of the 
immune responses responsible for the peri-exposure protection should be 
defined and evaluated. Unfortunately, many of the advanced tools and reagents 
are still underdeveloped or unavailable to study this in the hamster model. 
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	 Hopefully my study will further the use of the Syrian hamster model in the 
Hantavirus field and initiate more commercial reagent development. It is 
thought that the inclusion of the ZEBOVgp in the first cloning position of the 
rVSV genome is able to induce a rapid innate immune response that enhances 
the effect of the vaccine. Unfortunately, I was not able to explore the immune 
response to determine the mechanism of this short-term peri-exposure 
protection. However, future work towards this goal should be pursued. Defining 
the immunological mechanism would be an important milestone and would be 
valuable as it could be applied broadly to direct future vaccine development.  
With the recent publication of the hamster genome/transcriptome it could 
be valuable to explore methods that use deep sequencing to look at changes in 
transcription profiles in hamsters and used to look at differences in the 
transcriptomes / transcriptional changes of animals that get different vaccines to 
identify differential gene expression that could influence the immune responses 
in the hamster model. This could provide key insights to investigate the idea that 
ZEBOVgp targets the vaccine vectors to important immune cells strongly 
enhancing innate and adaptive immune responses and, thus improve protective 
efficacy which could, in turn, allow for further optimization of the vectors (and 
maybe unrelated vaccine platforms) to increase the protective efficacy and/or 
extend the window of time in which the vaccine could be effectively administered. 
Second, since the protection studies were performed with only 6 animals 
per group these experiments should be reproduced using larger group sizes to 
enhance the confidence in the improvement of the rVSVΔG-ZEBOVgp-ANDVgpc 
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	 over the other bivalent and monovalent rVSVs. In addition, the results should 
be confirmed in a second animal model if one is developed. Preferentially, the 
second animal model would be a nonhuman primate model to evaluate safety 
and immunology before advancing to human trials 
Overall this study has greatly advanced the understanding that the 
inclusion of a second glycoprotein from a completely unrelated virus (ZEBOVgp) 
can stimulate the immune system in such a way that there is an enhancement of 
the post-exposure protection of hamsters from a ANDV challenge. Finally, it may 
also be important in answering questions about the overall use of vaccines and 
other therapeutics that are used in post-exposure protection from other viral 
illnesses.  
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